News from adamas pharmaceuticals, inc A wide array of domestic and global news stories; news topics include politics/government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle. Articles that appear in this section may be written in English or other languages.

Latest

Jun 16, 2014, 16:01 ET Adamas Pharmaceuticals To Present At JMP Securities Healthcare Conference 2014

 Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS) today announced that Gregory T. Went, PhD., Chief Executive Officer, will present at the JMP...


Jun 10, 2014, 08:31 ET Adamas Pharmaceuticals Announces Rater Training Data on ADS-5102 for Parkinson's Disease Patients with Levodopa-Induced Dyskinesia

 Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS) today presented data on the rater and subject training process utilized in the Phase 2/3 EASED...


Jun 09, 2014, 16:01 ET United States Patent Issued To Adamas Pharmaceuticals

Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS), today announced that the United States Patent and Trademark Office (USPTO) issued US Patent No....


Jun 09, 2014, 16:01 ET Adamas Pharmaceuticals Initiates Phase 3 Trial For ADS-5102 In Parkinson's Disease Patients With Levodopa-Induced Dyskinesia

Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS) announced today that it has initiated a pivotal Phase 3 clinical study of ADS-5102 (amantadine HCl), a...


May 29, 2014, 16:05 ET Adamas Pharmaceuticals Announces Data Update At The International Congress Of Parkinson's Disease And Movement Disorders

 Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS) today announced a poster presentation at the 18th International Congress of Parkinson's Disease...


May 20, 2014, 16:05 ET Adamas Pharmaceuticals Receives $25 Million Milestone Payment From Forest Laboratories

Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS) announced today that it has received a $25 million milestone payment from Forest Laboratories Holdings...


May 13, 2014, 16:00 ET Adamas Reports First Quarter 2014 Financial Results

Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS) today reported financial results for the quarter ended March 31, 2014. "During the first quarter we...


Apr 30, 2014, 11:25 ET Adamas Pharmaceuticals proporciona una actualización de datos sobre el fármaco ADS-5102 en la reunión anual de la Academia Americana de Neurología

Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS), una compañía farmacéutica de especialidades, presentó hoy datos sobre la eficacia...


Apr 30, 2014, 09:00 ET Adamas Pharmaceuticals Provides Data Update On ADS-5102 At The American Academy Of Neurology Annual Meeting

Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS), a specialty pharmaceutical company, today presented data on the safety and efficacy of ADS-5102 for...


Apr 23, 2014, 16:00 ET Adamas Pharmaceuticals Announces Data Update At American Academy Of Neurology Annual Meeting

 Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS), a specialty pharmaceutical company, today announced a poster presentation at the American Academy...


Apr 15, 2014, 16:00 ET Adamas Pharmaceuticals Announces Closing of Its Initial Public Offering

 Adamas Pharmaceuticals, Inc. (Adamas) (Nasdaq:ADMS), a specialty pharmaceutical company, today announced the closing of its initial...


Apr 09, 2014, 18:55 ET Adamas Pharmaceuticals Announces Pricing Of Its Initial Public Offering

Adamas Pharmaceuticals, Inc. (Adamas), a specialty pharmaceutical company, today announced the pricing of its initial public offering of 3,000,000...


Jan 09, 2014, 09:00 ET Adamas Pharmaceuticals gana $40 millones en pagos por cumplimiento de hitos de Forest Laboratories para MDX-8704

Adamas Pharmaceuticals, Inc. hoy anunció que ha recibido $40 millones en pagos por cumplimiento de hitos de Forest Laboratories Holdings...


Jan 09, 2014, 09:00 ET Adamas Pharmaceuticals Earns $40 Million in Milestone Payments from Forest Laboratories for MDX-8704

 Adamas Pharmaceuticals, Inc. announced today that it has received $40 million in milestone payments from Forest Laboratories Holdings Limited...


Oct 02, 2013, 11:30 ET Adamas Pharmaceuticals presenta datos clínicos positivos para ADS-5102, un tratamiento para la disquinesia inducida por levodopa, en el Congreso Mundial del Parkinson

- Los resultados de la prueba EASED fase 2/3 demuestran un incremento de aproximadamente tres horas de período de respuesta a los medicamentos...


Oct 02, 2013, 11:30 ET Adamas Pharmaceuticals Presents Positive Clinical Data For ADS-5102, A Treatment For Levodopa-Induced Dyskinesia, At The World Parkinson's Congress

Adamas Pharmaceuticals, Inc. presented positive results today from the Phase 2/3 EASED™ clinical trial of ADS-5102 at the World Parkinson's...


Jun 18, 2013, 08:00 ET Adamas Pharmaceuticals Presents Positive Phase 2/3 Results For ADS-5102 For The Treatment Of Levodopa-Induced Dyskinesia (LID) In Parkinson's Disease

Adamas Pharmaceuticals, Inc. presented final results today from a Phase 2/3 clinical trial of ADS-5102 (amantadine HCl extended release) capsules...


Jun 10, 2013, 08:00 ET Adamas Pharmaceuticals To Report Positive Phase 2/3 Results For ADS-5102 For The Treatment Of Levodopa-Induced Dyskinesia In Parkinson's Disease

Adamas Pharmaceuticals, Inc. announced today that the Company's Phase 2/3 EASED™ (Extended Release Amantadine Safety and Efficacy Study in...


Apr 22, 2013, 08:30 ET Adamas Pharmaceuticals Announces Issuance of First US Patent for Nurelin™ (Amantadine HCl Extended Release) Program

 Adamas Pharmaceuticals, Inc. announced today that the United States Patent and Trademark Office (USPTO) issued U.S. Patent No. 8,389,578...


Mar 20, 2013, 07:00 ET Adamas Pharmaceuticals Presents New Traumatic Brain Injury Data From Its Nurelin™ Program At American Academy Of Neurology Conference

EMERYVILLE, Calif., March 20, 2013 /PRNewswire/-- Adamas Pharmaceuticals, Inc. will present research results today from its NurelinTM...


Jun 04, 2012, 07:00 ET Adamas Pharmaceuticals Presents Update On Nurelin™ Program At Cambridge Healthtech Institute's Parkinson's Conference

 Adamas Pharmaceuticals, Inc., a privately held company, announced today that it will present an update on its Nurelin™ (amantadine HCl...


May 15, 2012, 07:00 ET Adamas Pharmaceuticals Announces Successful End-of-Phase 2 Meeting with FDA for Arimenda™

 Adamas Pharmaceuticals, Inc., a privately held company, announced today that it has held an End-of-Phase 2 meeting with the FDA to discuss the...


Sep 28, 2011, 07:00 ET Adamas Pharmaceuticals Initiates a Phase 2/3 Clinical Study of ADS-5102 for Parkinson's Disease

Adamas Pharmaceuticals, Inc., a privately held company, announced today that it has initiated a Phase 2/3 clinical trial of its proprietary...


Apr 28, 2010, 07:00 ET Adamas Pharmaceuticals' Triple Combination Antiviral Drug (TCAD) Therapy is Well Tolerated in a Pilot Study of Immunocompromised Patients With Influenza A

Adamas Pharmaceuticals, Inc., a privately held company, announced today the results from the first clinical study evaluating triple combination...


Mar 15, 2010, 06:30 ET Adamas Pharmaceuticals' TCAD Therapy Demonstrates Broad Spectrum Activity Against Susceptible and Resistant Strains of Influenza in Animal Models

Adamas Pharmaceuticals, Inc., a privately held company, announced today results from in vivo animal studies and in vitro tests demonstrating that...